APC 100

Drug Profile

APC 100

Alternative Names: APC-100; CPC-100

Latest Information Update: 21 Sep 2015

Price : $50

At a glance

  • Originator Wisconsin Alumni Research Foundation
  • Developer Adamis Pharmaceuticals Corporation
  • Class Anti-inflammatories; Antiandrogens; Antineoplastics; Small molecules
  • Mechanism of Action Androgen receptor antagonists; Antioxidants; Reactive oxygen species inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Prostate cancer

Most Recent Events

  • 19 Jan 2015 APC 100 is still in a phase I/IIa trial for Prostate cancer in USA
  • 21 Aug 2013 APC 100 is still in a phase I/IIa trial for Prostate cancer in USA
  • 31 Aug 2011 Phase-I/II clinical trials in Prostate cancer (late-stage disease, second-line therapy or greater) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top